26 results
424B5
MLYS
Mineralys Therapeutics Inc
11 Apr 24
Prospectus supplement for primary offering
4:35pm
by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor’s report providing additional … information about the audit and the financial statements;
reduced disclosure obligations regarding executive compensation in our periodic reports, proxy
DEF 14A
MLYS
Mineralys Therapeutics Inc
9 Apr 24
Definitive proxy
7:15am
, and reputational risk.
The audit committee reviews information regarding liquidity and operations and oversees our management of financial risks. Periodically … , the audit committee reviews our policies with respect to risk assessment, risk management, including with respect to cybersecurity, loss prevention
S-3
EX-1.2
bhfyffedoftf4kt53u3
21 Mar 24
Shelf registration
7:30am
S-3
qog0hfy2v5b5
21 Mar 24
Shelf registration
7:30am
8-K
EX-99.1
jt72i3jfu6nmmj9v
7 Nov 23
Mineralys Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
4:07pm
8-K
xa5is
14 Sep 23
Departure of Directors or Certain Officers
4:11pm
10-Q
EX-31.1
t1aass yaa
15 May 23
Quarterly report
5:25pm
10-Q
lup dwxyl7za0m8j0lo
15 May 23
Quarterly report
5:25pm